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OBJECTIVES: The aim of the present study was to assess the diagnostic 
delay and the associated factors in patients with cutaneous malignant mela-
noma. METHODS: We carried out a survey including medical record analysis in 
patients diagnosed within five years with cutaneous malignant melanoma at the 
Pécs Dermatological Clinic (n= 362).The study investigated the diagnostic delay, its 
risk factors as clinical and histological characteristics of the tumor, and patients’ 
sociodemographic factors. Chi-square test, Mann-Whitney U test, and Kruskall-
Vallis test was used with 95% probability level (p< 0.05). RESULTS: 195 females and 
167 males participated in the investigation. The mean age was 54.5+/-14.8. Breslow 
tumor thickness was below 1 mm in 48.1% of patients and above 4 mm in 12.2% of 
patients. 35.1% of patients consulted a doctors six or more months later than the 
symptoms had appeared. The mean delay was 8.1+/-15.6 months. The prolonged 
delay resulted in more expressed tumor thickness (p= 0.027). Tumor thickness and 
delay showed no significant difference in the case of the tumor type and ulceration 
(p> 0.05). A higher proportion of women discovered the abnormality compared with 
men (65.2% versus 34.8%; p< 0.001). The latter subjects were informed by their rela-
tives to examine themselves. The most common site of prevalence was the lower 
limb in females (78.5% of cases); the trunk in males (61.3% of cases) (p< 0.001). 
The most common symptom observed by patients was the increase in lesion 
size (50.3%). Its prevalence on the lower limb (p= 0.01) and the increase in lesion 
size (p< 0.001) was associated with significantly longer delay. CONCLUSIONS: 
The study provides essential information for developing education campaigns in 
the future involving awareness promotion related to lesions perceived as minor 
significance. The present study emphasizes the importance of mindfulness and 
skills in the early detection of tumors. Prevention should be a decisive factor in 
primary care.
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OBJECTIVES: To evaluate measurement properties of the Psoriasis Symptom 
Inventory (PSI) in moderate/severe plaque psoriasis (PsO). METHODS: A second-
ary analysis of pooled data from a Phase III study of brodalumab in moderate to 
severe PsO patients (n= 661) was conducted. Outcome measures included: PSI (as 
a daily electronic diary), Psoriasis Area and Severity Index (PASI), static Physician’s 
Global Assessment (sPGA), involved body surface area (BSA), Dermatology Life 
Quality Index (DLQI), and the 36-item Health Survey version 2 (SF-36v2). Analyses 
included: confirmatory factor analysis (CFA) and Rasch analysis (dimensionality 
and item performance); Cronbach’s α (internal consistency); intraclass correla-
tion coefficients (ICCs) among patients with stable disease (test-retest reliabil-
ity); Spearman correlations (convergent validity); analysis of variance (known 
groups validity and ability to detect change); and agreement (Kappa, k) between 
PSI responders (PSI total score≤ 8 with no item score> 1) and PASI 75/90, sPGA 
0/1, and DLQI 0/1 responders. RESULTS: Results supported unidimensionality, 
good item fit, ordered responses, and combining of items into a single total score. 
Cronbach’s α s were ≥ 0.92 at baseline. Test-retest ICCs were ≥ 0.95 (week 6 to 8). 
At baseline, moderate/strong correlations between PSI total score and DLQI item 1 
(skin symptoms; r= 0.69), DLQI symptoms and feelings domain (r= 0.66), and SF-36 
bodily pain (r= -0.58) supported convergent validity. PSI scores were significantly 
different (p< 0.001) among known PsO severity groups based on PASI (< 12 or ≥ 12), 
sPGA (0–1, 2–3, or 4–5), BSA (< 5, 5-10, or > 10), and DLQI (≤ 5 or > 5) at week 8 and 
12. At week 12, the PSI detected significant changes in PsO severity based on PASI 
(< 50; 50< 75; ≥ 75) and sPGA (0/1; ≥ 2), and showed good agreement (k≥ 0.66) between 
PSI response and PASI, sPGA, and DLQI responses. CONCLUSIONS: The PSI dem-
onstrated excellent reliability, validity, and ability to detect change in severity of 
psoriasis signs and symptoms.
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OBJECTIVES: Patients with Hidradenitis Suppurativa (HS) experience painful 
abscesses and nodules primarily in the skin flexures, along with other disease-
related impact and symptoms, which can further diminish their health-related 
quality of life. No HS-specific tools exist to assess those symptoms and impacts. 
We aimed to report the development and initial psychometric evaluation of the 
Hidradenitis Suppurativa Symptom Assessment (HSSA) and the Hidradenitis 
Suppurativa Impact Assessment (HSIA). METHODS: The HSSA and HSIA were 
developed based on a literature review and concept elicitation interviews with 
HS patients (n= 20). Following initial construction, the questionnaires were cog-
nitively debriefed among HS patients (n= 20) to test their readability and com-
prehensiveness. Next, the HSIA and HSSA were implemented in a multi-center, 
non-interventional study with HS patients (n= 40) to evaluate their item and scale 
OBJECTIVES: Pressure ulcers (PU) are distressing events, caused when skin and 
the underlying tissues are placed under pressure sufficient to impair blood supply. 
They can have a substantial impact on quality of life, and have significant resource 
implications, with extended hospital stays and significant staff time devoted to 
treating the more severe cases. Repositioning is a key prevention strategy, but 
can be resource intensive, leading to variation in practice. This economic analysis 
formed part of the National Institute for Health and Care Excellence (NICE) clinical 
guideline on PU prevention and management, and was conducted to identify the 
most cost-effect repositioning strategy for the prevention of PU. METHODS: The 
clinical inputs to the model were taken from the systematic review of clinical data 
conducted for the guideline. The model population was elderly people in a nurs-
ing home; this represents a group at high risk of developing a PU. The economic 
model was developed in consultation with members of the guideline development 
group (GDG), and took the perspective of the UK National Health Service. Outcomes 
were expressed as costs and quality adjusted life years (QALYs). RESULTS: Despite 
being marginally more clinically effective, 2 and 4 hourly repositioning is not cost-
effective (compared to 4 hourly repositioning) for this high risk group of patients 
at a cost-effectiveness threshold of £20,000 per QALY. The ICER was £1,854,070 per 
QALY. CONCLUSIONS: 2 and 4 hourly repositioning is not cost-effective (compared 
to 4 hourly repositioning) in the UK for the group of patients analyzed here. These 
results were used to inform the guideline recommendations. FUNDING: This work 
was undertaken by the National Clinical Guideline Centre, which received funding 
from NICE. The views expressed in this publication are those of the authors and 
not necessarily of the institute.
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OBJECTIVES: To evaluate the cost-effectiveness of ranibizumab compared with 
aflibercept for the treatment of neovascular (wet) age-related macular degenera-
tion AMD from the UK healthcare provider perspective. METHODS: A patient 
simulation model was developed with best corrected visual acuity (BCVA) used 
as a marker of disease progression. Baseline patient characteristics were based 
on the EXCITE Phase III study. Change in BCVA for Year 1 and Year 2 were based 
on a network meta-analysis. Beyond Year 2 or after treatment discontinuation, 
BCVA in the treated eye was modelled using natural history data for wet AMD 
patients. Natural history data for the general population was used to model the 
untreated eye. BCVA change in each eye was modelled independently. A prob-
ability of developing bilateral disease was applied throughout the model. Utility 
values were estimated by a regression analysis of BCVA in the better-seeing 
eye (BSE) and in the worse-seeing eye (WSE). Three scenarios based on differ-
ent treatment and monitoring schedules were analyzed; pro-re-nata (PRN), treat 
and extend (T&E), observe and extend (O&E). The model assumed that 50% of 
patients were treated via one-stop monitoring, and 50% with two-stop moni-
toring. RESULTS: The difference in lifetime costs associated with ranibizumab 
(0.5mg) ranges from a saving of £22 with T&E regimen, to a reduction of £7,416 
with a PRN regimen. In addition, ranibizumab was associated with lifetime 
quality-adjusted life years (QALYs) of 5.07 compared with 5.06 for aflibercept 
and as a consequence dominated aflibercept. Probabilistic sensitivity analysis 
suggests that the probability of ranibizumab (0.5mg) being cost-effective with 
a T&E regimen is 27% at a £20,000 threshold, and 30% at a £30,000 threshold. 
With a PRN regimen, the probability of cost-effectiveness was 86% at a £20,000 
threshold and 86% at a £30,000 threshold. CONCLUSIONS: Ranibizumab domi-
nates aflibercept for patients with neovascular AMD irrespective of treatment 
regimen.
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OBJECTIVES: The World Health Organization reports that India’s rates of debili-
tating hearing loss are more than double rates in Europe and North America. 
With a population over 1.25 billion, India’s burden of hearing loss is extremely 
high. The cochlear implant (CI) is a highly effective treatment, providing some 
hearing to the deaf; however, CI use is extremely limited in India due to device 
cost, low incomes, limited medical and audiology expertise, and lack of aware-
ness. The objective of this study is to estimate the cost of a CI device whose use 
would be considered cost-effective in India for 1-year old children—the subgroup 
with the greatest utility gain. METHODS: The lifetime QALYs gained and payer 
costs are estimated based on a literature review and Indian life tables, and are 
discounted at 3% annually. The threshold incremental cost-utility ratio (ICUR) is 
considered at 3x, 2x, and 1x per capita gross domestic product (PCGDP). Given 
cost estimates of pre-implant evaluations, surgery costs, post-implant audiol-
ogy care, device upkeep, and the medical costs of complications and revision 
surgery, the ICUR equation is solved to determine the maximum cost-effective 
device cost. RESULTS: The health utility gain for a CI device implanted in a 1-year 
old was estimated at 0.36 with confidence interval (0.29; 0.43). Lifetime QALY 
gain was 9.28 (7.47; 11.03). Lifetime costs excluding the device cost were $14,895 
($10,639--$20,853). Given a PCGDP of $1,666, the cost-effectiveness willingness-
to-pay thresholds for maximum device cost for 3x, 2x and 1x PCGDP were $24,664 
($10,973; $36,664), $11,477 ($36; $20,896) and -$1,709 (-$10,242; $5,129), respec-
tively. The current minimum price of the device is ~$12,000. CONCLUSIONS: CIs 
in 1-year olds would be cost-effective in India based on a threshold of 3x or 2x 
PCGDP, but medical and device costs would have to be reduced to meet a 1x PCGDP 
threshold.
